Foamable microemulsions with fluconazole nanocrystals for the treatment of vulvovaginal candidiasis

Abstract

This proposal aims to develop fluconazole nanocrystals and incorporate them into foamable microemulsions, for the treatment of vaginal fungal infections. Antifungal treatments available can be long, uncomfortable, and do not reach the whole affected area, leave residues, and sometimes cause adverse effects as burning, itching, swelling, given the currently formulations developed. Keeping this is mind, microemulsions may be an alternative dosage form because they can increase the solubility and permeation of poorly soluble drugs, which allows lower concentrations and fewer applications to be required, besides being able to be foamed if formulated appropriately. In addition, foams do not leave stains or residues, and can expand and cover body cavities. After developing the foamable microemulsions, they will be characterized for their physicochemical and foaming properties and release profile. However, fluconazole is a difficult drug to deliver and formulate because of its hydrophobic character. Thus, developing fluconazole nanocrystals may be a way out to enhance the solubility and bioavailability of the drug. We aim to combine the advantages of microemulsion and nanocrystals, creating an appropriate dosage form for the treatment of vulvovaginal candidiasis a recurrent disease that ravages women around the world. (AU)